Skip to main content

Table 1 Descriptive characteristics by detection method 1999–2016 (n = 6603)

From: Breast cancer distant recurrence lead time interval by detection method in an institutional cohort

  PtD MamD p value
(n = 2566) (n = 4037)
Stage N (column %) N (column %)  
 I 792 (31%) 2772 (69%) <.001
 II 1314 (51%) 1108 (27%)  
 III 460 (18%) 157 (4%)  
Age
 40–49 950 (55%) 765 (45%) <.001
 50–64 1216 (36%) 2189 (64%)  
 65–74 400 (27%) 1083 (73%)  
 Mean age (range, F statistic) 54 (40–74) 58 (40–74) <.001
Race
 White 1986 (37%) 3388 (63%) <.001
 Non-White 580 (47%) 649 (53%)  
Hormone receptor status
 HR+ 2081 (36%) 3641 (64%) <.001
HER2 status
 Her2+ (HR- or HR+) 458 (46%) 534 (54%) <.001
HR/HER2 status at initial diagnosis
 HR+/HER2- 1718 (36%) 3110 (64%) <.001
 HR+/HER2+ 332 (45%) 399 (55%)  
 HR−/HER2- 340 (61%) 216 (39%)  
 HR−/HER2+ 126 (49%) 134 (51%)  
Histologic type initial primary breast tumor
 Ductal 2122 (39%) 3312 (61%) .287
 Lobular 258 (39%) 411 (61%)  
 Lobular/Ductal mixed 120 (40%) 177 (60%)  
 Other cancer 64 (33%) 133 (67%)  
Nuclear grade initial primary breast tumor
 Low/Intermediate 1189 (31%) 2675 (69%) <.001
 High 1340 (51%) 1289 (49%)  
Histologic grade initial primary breast tumor
 Low/Intermediate 583 (29%) 1447 (71%) <.001
 High 1943 (44%) 2498 (56%)  
 Tumor size (mean, range, F statistic) 2.91 (.10, 18.00) 1.51 (.05, 17.00) <.001
 # Positive nodes (mean, range, F statistic) 1.67 (0–44) .57 (0–35) <.001
Treatment
 Surgery only 339 (36%) 614 (64%) <.001
 Surgery/radiation 575 (22%) 1997 (78%)  
 Surgery/chemotherapy 412 (53%) 372 (47%)  
 Surgery/radiation/chemotherapy 1240 (54%) 1054 (46%)  
Distant recurrence
 Yes 289 (68%) 133 (32%) <.001